Navigation Links
Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
Date:3/17/2008

of Tianyin's top strategic partners and has awarded the Company a $3.66 million distribution contract for 2008 covering most of the PRC for Azithromycin and other products. Margins associated with this product are in line with the Company's blended average during the past year. This collaboration will help speed the market entry of Tianyin's Azithromycin Dispersible Tablets and enable the Company to leverage its National SFDA manufacturing approval to gain market share throughout China.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filin
'/>"/>

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasdaq: CHBT ... in the manufacture, research, development, marketing and,distribution of ... four patents to the State Intellectual Property Office ... These applications are patents for a ...
... Ueno, Ltd. announced on July 29 after discussing its R&D policy ... day and determined the R&D items as follows. , , ... ophthalmologic & dermatological fields that are its priority and exclusive areas, ... 1. Development code UF-021 (eye diseases) , , ...
... , , PHILADELPHIA, July 30 eResearchTechnology, Inc. (ERT), ... and other services to the biopharmaceutical, medical device and related industries, announced ... 2009. Unless otherwise noted, all comparative numbers refer to changes from ... , Highlights of the second quarter of 2009 were: ...
Cached Biology Technology:China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 2China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations 3R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3ERT Reports Second Quarter 2009 Results 2ERT Reports Second Quarter 2009 Results 3ERT Reports Second Quarter 2009 Results 4ERT Reports Second Quarter 2009 Results 5ERT Reports Second Quarter 2009 Results 6ERT Reports Second Quarter 2009 Results 7ERT Reports Second Quarter 2009 Results 8ERT Reports Second Quarter 2009 Results 9ERT Reports Second Quarter 2009 Results 10ERT Reports Second Quarter 2009 Results 11ERT Reports Second Quarter 2009 Results 12
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
(Date:8/28/2014)... Invasives is now available from the Lady Bird Johnson ... for identifying harmful non-native plant, insect and other invasive ... States cause about $137 billion in economic and other ... kill native plants and more. , "By having streamlined ... invasive species occur, we,re more likely to catch these ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... called nestin to a particularly deadly form of breast ... earlier detection and better treatment. , In the ... Medical School demonstrate that nestin could represent a selective ... aggressive cancer with similarities to mammary stem cells, the ...
... long term hip replacement surgery may lie in the genes, ... the Rheumatic Diseases. , The researchers analysed genetic variations in ... after hip replacement in the 10 years following surgery. ... “aseptic loosening,?which describes a condition in which the artificial joint ...
... leopard found on the islands of Borneo and Sumatra is ... was originally thought to be the same species as the ... analysis conducted at the U.S. National Cancer Institute shows that ... to the differences between other large cat species like lions, ...
Cached Biology News:Selective marker found to indicate aggressive form of breast cancer 2New species declared: Clouded leopard on Borneo and Sumatra 2
... IT siRNA Tracker Intracellular Localization Kit provides ... and deliver siRNA, of your design, in ... vitro tracking experiments. Subcellular localization and functional ... monitored following introduction of the labeled siRNA ...
... Beacon 2000 instrument can be used as ... 2000 Data Manager Software provides the means ... from the instrument. These data can then ... spreadsheets, such as Microsoft Excel or Lotus ...
... for the study of protein:protein interactions from ... that interact with GST•Tag™, S•Tag™, or ... using affinity resins for the tags, and ... filter. The complexes are eluted with sample ...
... Microarray Kit (V2), 22K is useful for investigating ... Each microarray contains content derived from the ATH1 ... Research (TIGR) and represents 21,500 genes. ... x 3? glass slides each containing an identical ...
Biology Products: